Abstract 3414
Background
Angiosarcoma (AS) is a rare malignancy with a heterogeneous clinical presentation and genetic background. Different clinical AS subtypes can be envisaged, including: visceral, deep-seated soft tissue (ST), radiation induced (RT) and UV associated (UV) origin. To better understand their distinct biology and clinical outcome we investigated DNA methylation profiles, chromosomal stability and survival of these four subtypes.
Methods
After ethical approval, FFPE samples of AS from visceral, ST, RT and UV origin were collected from a nationwide search by the Dutch nationwide network and registry of histo- and cytopathology. DNA was extracted for methylation profiling with the Illumina Infinium MethylationEPIC array (German Cancer Research Center, Heidelberg, Germany). Quality control and unsupervised hierarchical clustering based on the 1% most varying methylation probes took place at Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Copy number profiles were generated for chromosomal stability assessment. Anonymized clinical data were obtained from the Netherlands Cancer Registry.
Results
DNA methylation profiling and unsupervised hierarchical clustering of 36 AS samples (6 visceral, 5 ST, 14 RT, 11 UV), revealed two main clusters (A and B) and four subclusters (Table). The different clusters corresponded with clinical origin, showing enrichment of UV cases in cluster A1 and RT cases in cluster A2. Cluster A showed significantly more chromosomal aberrations and better median overall survival compared to cluster B (22.2 vs 5.5 months, p = 0.046).Table:
1711P Cluster characteristics
Cluster | A1 | A2 | B1 | B2 |
---|---|---|---|---|
Patients | 7 | 11 | 7 | 11 |
Subtype | 7 UV | 10 RT, 1 ST | 4 ST, 3 Visceral | 4 RT, 4 UV, 3 Visceral |
Median survival (months, range) | 22 (2-106) | 23 (1-281) | 4 (2-55) | 7 (0-40) |
Conclusions
In this novel DNA methylation profiling study, we demonstrated for the first time four different AS clusters. These clusters strongly correlated with clinical origin, chromosomal stability and overall survival. Further research is warranted in a larger patient cohort to better define the clinical significance of the different clusters.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
HDKT (Honderdduizend Keer een Tientje).
Disclosure
I.M.E. Desar: Research grant / Funding (institution): Novartis. W.T. van der Graaf: Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
3811 - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Presenter: Santiago Ponce Aix
Session: Poster Display session 1
Resources:
Abstract
1311 - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
Presenter: Aaron Tan
Session: Poster Display session 1
Resources:
Abstract
3482 - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Presenter: Sanne Huijberts
Session: Poster Display session 1
Resources:
Abstract
4749 - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Presenter: Desiree Hao
Session: Poster Display session 1
Resources:
Abstract
4530 - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
Presenter: Funda Meric-Bernstam
Session: Poster Display session 1
Resources:
Abstract
4280 - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster Display session 1
Resources:
Abstract
6144 - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Presenter: Christopher Jackson
Session: Poster Display session 1
Resources:
Abstract